Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine

Gene Therapy volume 6, pages 865–872 (1999)Cite this article

Abstract

The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor α (FRα) as an additional antigen in order to study the efficacy of vaccination against a tumor expressing multiple antigens. A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12/FRα that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FRα. After vaccination mice were partially splenectomized and splenic lymphocytes frozen and used retrospectively to study in vitro CD8 T cell response related to the treatment outcome. Vaccination cured 50% of mice and the effect was CD8 T cell dependent. Mice either cured (responders) or not cured (nonresponders) by vaccination developed tumor-specific CTL. However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26- related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FRα antigen. CD8 from responder mice were characterized to release high levels of granulocyte–macrophage (GM)-CSF upon antigen stimulation. Tumors obtained from mice that died despite vaccination lost expression of the FRα transgene but maintained expression of endogenous C26 antigens. Immunoselection against FRα antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. Down-regulation of FRα antigen expression was due, at least in part, to methylation of retroviral vector long terminal repeat promoter since FRα expression was partially restored, ex vivo, by treatment with 5-aza-2′-deoxy-cytidine (aza). These results indicate that CD8 T cell-mediated immunoselection and production of GM-CSF are determining factors for the efficacy of tumor vaccines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Boon T, Coulie PG, Van den Eynde B . Tumor antigens recognized by T cells Immunol Today 1997 18: 267–268

    Article  CAS  PubMed  Google Scholar 

  2. Rosenberg SA . Cancer vaccines based on the identification of genes encoding cancer regression antigens Immunol Today 1997 18: 175–185

    Article  CAS  PubMed  Google Scholar 

  3. Mitchell MS . Active specific immunotherapy of melanoma Br Med Bull 1995 51: 631–646

    Article  CAS  PubMed  Google Scholar 

  4. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 1992 216: 463–482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Parmiani G, Colombo MP, Melani C, Arienti F . Cytokine gene transduction in the immunotherapy of cancer Adv Pharmacol 1997 40: 259–308

    Article  CAS  PubMed  Google Scholar 

  6. Musiani P et al. Cytokines, tumor-cell death and immunogenicity: a question of choice Immunol Today 1997 18: 32–36

    Article  CAS  PubMed  Google Scholar 

  7. Jager E et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T cell responses: evidence for immunoselection of antigen-loss variants in vivo Int J Cancer 1996 66: 470–476

    Article  CAS  PubMed  Google Scholar 

  8. Lehmann M et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection Eur J Immunol 1995 25: 343–347

    Article  Google Scholar 

  9. Cormier JN et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo Int J Cancer 1998 75: 517–524

    Article  CAS  PubMed  Google Scholar 

  10. Huang AS et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product Proc Natl Acad Sci USA 1996 93: 9730–9735

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rodolfo M et al. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T cell receptors Int J Cancer 1994 57: 440–447

    Article  CAS  PubMed  Google Scholar 

  12. Coney LR et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein Cancer Res 1991 51: 6125–6132

    CAS  PubMed  Google Scholar 

  13. Mantovani LT et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19 Eur J Cancer 1994 30: 363–369

    Article  Google Scholar 

  14. Trinchieri G . Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptative immunity Annu Rev Immunol 1995 13: 251–276

    Article  CAS  PubMed  Google Scholar 

  15. Rodolfo M et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines J Immunol 1996 157: 5536–5542

    CAS  PubMed  Google Scholar 

  16. Salgaller ML . Monitoring of cancer patients undergoing active or passive immunotherapy J Immunother 1997 20: 1–14

    Article  CAS  PubMed  Google Scholar 

  17. Arienti F et al. Limited antitumor T cell response in melanoma patients vaccinated with IL-2 gene-transduced allogeneic melanoma cells Hum Gene Ther 1996 7: 1955–1963

    Article  CAS  PubMed  Google Scholar 

  18. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA . Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides Cancer Res 1996 56: 4749–4757

    CAS  PubMed  Google Scholar 

  19. Cormier JN et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A Cancer J Sc Am 1997 3: 37–44

    CAS  Google Scholar 

  20. Saito S et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines Cancer Res 1994 54: 3516–3520

    CAS  PubMed  Google Scholar 

  21. Brichard V et al. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815 Eur J Immunol 1995 25: 664–671

    Article  CAS  PubMed  Google Scholar 

  22. Vanderlugt CJ, Miller SD . Epitope spreading Curr Opin Immunol 1996 8: 831–836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Van Waes C et al. Immunodominance deters the response to other tumor antigens thereby favouring escape: prevention by vaccination with tumor variants selected with cloned cytolytic cells in vitro Tissue Antigens 1996 47: 399–407

    Article  CAS  PubMed  Google Scholar 

  24. Maeurer MJ et al. Tumor escape from immune recognition; lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen J Clin Invest 1996 98: 1633–1641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Seung S, Urban JL, Schreiber H . A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target J Exp Med 1993 178: 933–940

    Article  CAS  PubMed  Google Scholar 

  26. Weber M et al. Expression of the Mage-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine Cancer Res 1994 54: 1766–1771

    CAS  PubMed  Google Scholar 

  27. De Smet M et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation Proc Natl Acad Sci USA 1996 93: 7149–7153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Habers K et al. DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning Proc Natl Acad Sci USA 1981 78: 7609–7613

    Article  Google Scholar 

  29. Tahara H et al. Effective eradication of established murine tumors with IL-12 therapy using a polycistronic retroviral vector J Immunol 1995 154: 6466–6474

    CAS  PubMed  Google Scholar 

  30. Hock H et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor α, or interferon γ Proc Natl Acad Sci USA 1993 90: 2774–2778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Goedegebuure PS et al. Reactivity of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy Surg Oncol 1994 3: 79–85

    Article  CAS  PubMed  Google Scholar 

  32. Schwartzentruber DJ et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2 J Clin Oncol 1994 12: 1475–1508

    Article  CAS  PubMed  Google Scholar 

  33. Chang AE et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2 J Clin Oncol 1997 15: 796–807

    Article  CAS  PubMed  Google Scholar 

  34. Grabstein KH et al. Induction of macrophage tumoricidal activity by granulocyte–macrophage colony-stimulating factor Science 1986 232: 506–508

    Article  CAS  PubMed  Google Scholar 

  35. Thomassen MJ et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte–macrophage colony-stimulating factor therapy Cancer Res 1991 51: 857–862

    CAS  PubMed  Google Scholar 

  36. Zilocchi C et al. IFNγ-independent rejection of IL-12-transduced carcinoma cells requires CD4+ T cells and GM-CSF J Exp Med 1998 188: 133–143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Eberl G et al. Immunodominance of cytotoxic T lymphocyte epitopes coinjected in vivo and modulation by interleukin-12 Eur J Immunol 1996 26: 2709–2716

    Article  CAS  PubMed  Google Scholar 

  38. Miotti S et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity Int J Cancer 1987 39: 297–303

    Article  CAS  PubMed  Google Scholar 

  39. Langhorne J . Limiting dilution analysis of precursors of cytotoxic T lymphocytes. In: Lefkovits I, Pernis B (eds). Immunological Methods. Vol2 Academic Press: New York, 1981, pp221–231

Download references

Author information

Authors and Affiliations

  1. Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

    M Rodolfo, C Zilocchi, B Cappetti, G Parmiani, C Melani & M P Colombo

Authors
  1. M Rodolfo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Zilocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Cappetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Melani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M P Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodolfo, M., Zilocchi, C., Cappetti, B. et al. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Ther 6, 865–872 (1999). https://doi.org/10.1038/sj.gt.3300874

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300874

Keywords

This article is cited by

Search

Advanced search

Quick links